Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw an uptick in trading volume on Friday . Approximately 128,203 shares were traded during mid-day trading, a decline of 46% from the previous session’s volume of 239,306 shares.The stock last traded at $22.08 and had previously closed at $22.09.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CHGCY shares. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Finally, UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 0.6%

The firm has a market cap of $73.17 billion, a PE ratio of 24.16 and a beta of 0.60. The stock’s 50 day moving average price is $22.45 and its 200 day moving average price is $25.67.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, July 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%. Analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.